Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafasitamab + lenalidomide + R-CHOP
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Tafasitamab + lenalidomide + R-CHOP** is a pharmaceutical combination regimen comprising an anti-CD19 monoclonal antibody (tafasitamab), an immunomodulatory agent (lenalidomide), and the standard first-line chemotherapeutic protocol for diffuse large B-cell lymphoma (DLBCL) known as R-CHOP, which includes rituximab (anti-CD20 monoclonal antibody), cyclophosphamide, doxorubicin, vincristine, and prednisone[1][3][7].\nTafasitamab enhances immune response by increasing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) through its Fc-engineered structure, specifically targeting CD19 on B-cells[6]. Lenalidomide acts as an immunomodulatory agent, promoting NK cell activity and synergistically improving the efficacy of anti-CD19 therapy, while also exhibiting direct antineoplastic effects. The R-CHOP regimen utilizes cytotoxic and immunotherapeutic agents to target malignant B cells through distinct mechanisms.\nThis combination is being investigated as front-line therapy for untreated DLBCL in phase 3 clinical trials (frontMIND), following promising safety and efficacy data from earlier studies[1][3][7].
- Other names
- tafasitamab + lenalidomide + R-CHOP
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tafasitamab + lenalidomide + R-CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafasitamab + lenalidomide + R-CHOP.